Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00334204 · ClinicalTrials.gov registry record · Phase 4
Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?
A Phase 4 study, sponsored by University of Mississippi Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT00334204 is a Phase 4 study that was terminated before completion, run by University of Mississippi Medical Center. The registered enrollment target is 58 participants.
The verdict
NCT00334204, a Phase 4 study, was terminated before completion, sponsored by University of Mississippi Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
The kidneys are highly vascular organs and any trauma or surgery poses risk of severe bleeding. Platelet function is an integral part of the blood clotting during the initial, so-called vascular phase. So far no universally accepted, easy test has been available to measure platelet functions. Renal failure is a condition generally associated with bleeding due to platelet dysfunctions. This study is exploring the utility of a novel platelet function test, called Platelet Function Analyser-100 to predict bleed after percutaneous kidney biopsy. Platelet Function Analyser-100 will be measure before kidney biopsy along with routine blood tests. Subjects will undergo renal ultrasound before and after renal biopsy to verify post-biopsy bleeding events.
Interventions
- DEVICE measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2004-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00334204
The ClinicalTrials.gov registry entry for NCT00334204 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy is the first listed.
NCT00334204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00334204 about?
NCT00334204 is a clinical study titled "Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?". The kidneys are highly vascular organs and any trauma or surgery poses risk of severe bleeding. Platelet function is an integral part of the blood clotting during the initial, so-called vascular phase. So far no universally accepted, easy test has been available to measure platelet functions. Renal ...
What is the current status of trial NCT00334204?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2004-08. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00334204?
The interventions under investigation include: measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy (DEVICE).
Who is sponsoring clinical trial NCT00334204?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.